Stockscreener 앱 받기
1.49
0.68%
0.01
시간 외 거래:
1.56
0.07
+4.70%
전일 마감가:
$1.48
열려 있는:
$1.47
하루 거래량:
18,141
Relative Volume:
0.01
시가총액:
$4.94M
수익:
$3.25M
순이익/손실:
$-8.34M
주가수익비율:
-0.5785
EPS:
-2.5755
순현금흐름:
$-7.71M
1주 성능:
-1.32%
1개월 성능:
+132.78%
6개월 성능:
+24.17%
1년 성능:
-36.86%
1일 변동 폭
$1.47
$1.5651
1주일 범위
$1.47
$1.60
52주 변동 폭
$0.575
$5.50
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
명칭
Inmed Pharmaceuticals Inc
전화
(604) 669-7207
주소
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.49 | 5.00M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Inmed Pharmaceuticals Inc 주식(INM)의 최신 뉴스
InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN
Vivo Opportunity funds disclose major InMed (INM) insider share holdings - Stock Titan
Vivo Opportunity Fund Holdings Discloses Investment at InMed Pharmaceuticals with 21.7% Stake - TradingView
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status - TipRanks
InMed Regains Nasdaq $1.00 Bid-Price Compliance After 10 Consecutive Business Days - TradingView
Nasdaq confirms InMed (NASDAQ: INM) back in minimum bid-price compliance - Stock Titan
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
InMed Pharmaceuticals (INM) Q3 2025 Earnings: Narrower Loss Reported With No Revenue StreamWeak Earnings Momentum - newsline.com
InMed Pharmaceuticals Regains Compliance With Nasdaq Continued Listing Requirements - Moomoo
InMed Pharmaceuticals (INM) Pushes Higher: Testing Resistance at $1.66 After Mild GainsDescending Triangle - newsline.com
ADAR1/Manager Daniel Schneeberger reports 24.1% stake in InMed (NASDAQ: INM) - Stock Titan
InMed Pharmaceuticals regains Nasdaq compliance - Investing.com UK
InMed Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Australia
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - TMX Newsfile
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks
Squadron Master Fund discloses 9.8% stake in InMed Pharmaceuticals (INM) - Stock Titan
InMed Pharmaceuticals (INM) Shares Slide Over 3% as Biotech Volatility IntensifiesInstitutional Flow Picks - newsline.com
InMed Pharmaceuticals (INM) Holds Steady Near Key Support LevelsSentiment Shift - The Legal Advocate
INM | InMed Pharmaceuticals Inc. Common Insider Trading - Quiver Quantitative
InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesTrough Earnings Signal - Newser
InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser
InMed Pharmaceuticals and Mentari Announce Merger AgreementThe Legal Advocate - The Legal Advocate
InMed Pharmaceuticals Shares Surge Following Mentari Merger Announcement - HarianBasis.co
ADAR1-managed funds add 468,551 InMed (INM) shares in open-market buys - Stock Titan
InMed (INM) major holder ADAR1 reports 331,449 indirect shares on Form 3 - Stock Titan
InMed Pharmaceuticals Merges with Mentari Therapeutics to Target Migraine Prevention - HarianBasis.co
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com
/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire
Mentari Therapeutics: $290 Million Private Placement Supports Merger With InMed Pharmaceuticals To Advance Migraine Prevention Therapies - Pulse 2.0
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested - TechStock²
Mentari lists via InMed merger, takes $290m for migraine pipeline - The Pharma Letter
InMed Pharmaceuticals Lowers Armistice Preferred Investment Option Exercise Price from $16.60 to $0.80 - Minichart
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Th - GuruFocus
Law firm investigates InMed Pharmaceuticals' board over possible unfair sale to Mentari Therapeutics - Pluang
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire Inc.
Mentari, InMed Merge In Deal Backed By $290M Funding - Law360
InMed Pharmaceuticals, Inc. (INM) Stock: Climbs on $290M Private Placement and Migraine Pipeline Deal - parameter.io
InMed Pharmaceuticals and Mentari Therapeutics Announce $290M Merger to Advance Migraine Prevention Therapies - Minichart
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
InMed amends warrant terms, cuts exercise price to $0.80 - Investing.com UK
InMed Soars 100% on $290M Migraine Deal - TechStock²
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development - GuruFocus
Trending Stocks Today | Amesite Surges 150.6% - Moomoo
Inmed Pharmaceuticals Inc (INM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Inmed Pharmaceuticals Inc 주식 (INM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Vivo Opportunity, LLC | 10% Owner |
Jun 05 '26 |
Buy |
1.57 |
55,011 |
86,367 |
688,926 |
| Vivo Opportunity, LLC | 10% Owner |
May 21 '26 |
Buy |
1.69 |
34,000 |
57,460 |
574,011 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 08 '26 |
Buy |
1.52 |
32,500 |
49,400 |
718,444 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 02 '26 |
Buy |
1.52 |
22,848 |
34,729 |
625,766 |
| Vivo Opportunity, LLC | 10% Owner |
May 29 '26 |
Buy |
1.57 |
17,796 |
27,940 |
590,175 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 01 '26 |
Buy |
1.55 |
16,336 |
25,321 |
605,013 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 03 '26 |
Buy |
1.55 |
7,783 |
12,064 |
632,835 |
| Vivo Opportunity, LLC | 10% Owner |
Jun 04 '26 |
Buy |
1.57 |
6,743 |
10,587 |
638,960 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 19 '26 |
Buy |
1.54 |
468,551 |
721,548 |
800,000 |
0.95%
1.13%
자본화:
|
볼륨(24시간):